Synthetic Biologics ’ SYN-004 secures FDA breakthrough therapy status

Synthetic Biologics has secured breakthrough therapy designation for SYN-004 (ribaxamase) from the US Food and Drug Administration (FDA) to treat Clostridium difficile infection (CDI).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news